Alpha-1 antitrypsin deficiency affects roughly 100,000 Americans and has had no cure for the four decades it has been understood. Suddenly it is one of the most crowded targets in biotech. Beam Therapeutics, CRISPR Therapeutics, Prime Medicine, Wave Life Sciences, Tessera Therapeutics with Regeneron, and the newly launched, $230 million Serapha Bio are all developing one-time genetic therapies aimed at it, using several different editing technologies.
That is a lot of firepower for a rare disease. The reason is not that AATD suddenly became more urgent. It is that AATD is the near-perfect place to prove a gene-editing platform works, and the real contest underneath the race is less about curing one disease than about establishing which editing technology becomes the dominant tool for many. The disease is the test case. The platforms are the prize.
Why one mutation changes everything
To see why so many companies converged on the same target, you have to understand a specific genetic fact. Alpha-1 antitrypsin deficiency, in the large majority of severe cases, is caused by a single identical point mutation shared across the patient population, a change of one letter in the SERPINA1 gene, the same change in nearly everyone with the severe form.
That is unusual and enormously convenient. Most genetic diseases are caused by many different mutations scattered across a gene, which means a therapy correcting one mutation helps only the subset of patients who carry it. AATD is close to the opposite. Fix that one letter and you have, in principle, a single therapy that works for most of the patient population, a one-size-fits-all genomic correction. For a technology whose entire promise is precisely correcting single-letter errors in DNA, AATD is almost a designed demonstration.
There is a second feature that makes it ideal. The relevant gene acts in the liver, and the liver is the organ gene-editing tools are best at reaching, because the lipid nanoparticles and other delivery vehicles the field relies on naturally accumulate there. Delivery, getting the editing machinery into the right cells, is one of the hardest problems in the field, and AATD sidesteps much of it by living in the most accessible organ. A single, shared, correctable mutation in the easiest-to-reach tissue is about as clean a proving ground as genetic medicine offers.
Why the platforms matter more than the disease
Here is the part that reframes the whole race. Most of the companies competing are not primarily AATD companies. They are platform companies, each built around a different method of editing DNA, and AATD is the first serious clinical test of the method.
The approaches differ in kind. Beam and, in its own way, Serapha use base editing, which chemically changes one DNA letter into another without cutting the double helix. CRISPR Therapeutics is using a newer platform it calls SyNTase editing. Prime Medicine uses prime editing, a search-and-replace approach. Tessera uses what it calls Gene Writing, developed under the R&D leadership of physician-executive Michael Severino before he left in 2026 to become Sarepta's new CEO. Wave uses RNA editing, which edits the RNA message rather than the DNA itself, a reversible approach rather than a permanent one. These are genuinely different technologies with different strengths, risks, and intellectual-property positions, and each company believes its method is the future of genetic medicine.
AATD is where several of them get their first real answer. Because the disease is such a clean target, success or failure there is unusually informative about the platform itself rather than about the peculiarities of the disease. If a company's editor precisely corrects the SERPINA1 mutation, raises the protein to healthy levels, and does so safely and durably in humans, that is powerful evidence the platform will work on the next single-mutation liver disease, and the one after that. The company that wins AATD is not just first to a rare-disease market. It has a validated, de-risked platform it can point at a long list of other genetic conditions, which is worth far more than one rare-disease franchise.
That is why the capital and the competition are disproportionate to the size of the disease. Investors are not only buying a potential AATD cure. They are buying a call option on a platform that, if it works here, works widely.
Reading the standings without overreading them
The competitive positions are real but should be held loosely, because in gene editing the order of the field can change with a single data readout.
Beam is generally regarded as the most advanced, with pivotal trials for its AATD base editor expected to begin in the second half of 2026 under a potential accelerated-approval pathway. Serapha launched with human proof-of-concept data generated in Shanghai and a therapy licensed from the Chinese biotech YolTech, having cleared US regulatory review in March 2026. CRISPR Therapeutics, Prime Medicine, and the Tessera-Regeneron partnership are earlier, filing to begin or just beginning clinical trials. Wave took a different path, reclaiming full rights to its RNA-editing candidate from GSK in early 2026 on the argument that a focused biotech could move a rare-disease drug faster than a large respiratory-focused pharma.
Two cautions about reading those standings. First, "most advanced" is not "winner." A safety signal, a manufacturing problem, or disappointing durability can reorder the field overnight, and a later entrant with a cleaner or more durable edit can leapfrog a leader. Being first to pivotal trials matters, and it does not settle anything. Second, the approaches are different enough that more than one could succeed for different patient subgroups or with different risk-benefit profiles, so this is not necessarily winner-take-all. A permanent DNA edit and a reversible RNA edit are genuinely different products, and some patients or physicians may prefer one over the other regardless of which reached the market first.
The geopolitics that complicate the picture
One thread here is not purely scientific, and it is worth naming plainly. Serapha's therapy was licensed from a Chinese biotech and its proof-of-concept data were generated in Shanghai, and it is entering the US market against a backdrop of the BIOSECURE Act, legislation aimed at restricting US biotech's reliance on Chinese partners.
That creates a real and separate source of uncertainty layered on top of the science. A therapy with a strong scientific foundation can still face regulatory and political friction if its origins run through a jurisdiction that US policy is actively trying to decouple from. Whether that friction materializes is unknown, and it is a genuine risk factor for one of the better-funded entrants that has nothing to do with whether the editing works. It is a reminder that in the current environment, where a drug's science was developed can matter alongside how well it works.
The honest frame
Two things are worth holding together. AATD patients, who have waited four decades with only augmentation therapy that treats the deficiency rather than the cause, genuinely stand to benefit, and the intensity of competition is good news for them, since multiple well-funded shots at a one-time cure improve the odds that at least one succeeds. On the disease's own terms, this crowded race is something to welcome.
At the same time, the reason the race is this crowded is strategic rather than sentimental. AATD is the cleanest available proving ground for gene-editing platforms, a single shared mutation in the most accessible organ, and the companies are competing there because winning validates a technology worth far more than the disease itself. Both things are true, and neither diminishes the other. The patients get the benefit of intense competition precisely because the target is scientifically irresistible to platform companies.
For anyone watching the field, the useful lens is to treat AATD results over the next couple of years as a referendum on gene-editing approaches as much as on an AATD cure. When Beam's pivotal data arrive, or when the earlier entrants report, the immediate question will be whether a given patient population gets a cure. The larger question, the one the capital is really chasing, is which way of editing the human genome just proved it works, because whoever wins the cleanest genetic disease has earned the right to attempt all the messier ones. The disease is the proving ground. The platform is what everyone is actually racing for.
Primary sources
- Tech Times for Serapha Bio's $230 million launch, the therapy licensed from YolTech Therapeutics, the roughly 100,000 affected Americans, the single shared SERPINA1 point mutation, Beam's position as most advanced with pivotal trials expected in the second half of 2026, and the BIOSECURE Act context.
- CRISPR Therapeutics' release for the CTX460 SyNTase editing program, its preclinical correction data, and mid-2026 clinical entry.
- Prime Medicine's release for its prime-editing AATD program and 2026 IND/CTA filing plans.
- Regeneron's release for the Tessera collaboration on TSRA-196, the $150 million to Tessera, the end-of-year IND expectation, and Michael Severino's role as Tessera CEO at the time.
- BioPharma Dive for Wave Life Sciences reclaiming global rights to its RNA-editing candidate WVE-006 from GSK; BioSpace and a Taylor & Francis review for background on prior AATD programs and why the disease's single-gene basis makes it a favored target.